| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
SONX Stock Overview
Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada.
Sonendo Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.63 |
| 52 Week High | US$12.24 |
| 52 Week Low | US$1.40 |
| Beta | 0 |
| 1 Month Change | -9.44% |
| 3 Month Change | -40.51% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.28% |
Recent News & Updates
Shareholder Returns
| SONX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -12.4% | 1.9% | 3.2% |
| 1Y | n/a | -19.1% | -10.2% |
Return vs Industry: Insufficient data to determine how SONX performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how SONX performed against the US Market.
Price Volatility
| SONX volatility | |
|---|---|
| SONX Average Weekly Movement | 12.2% |
| Medical Equipment Industry Average Movement | 9.4% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SONX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SONX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 234 | Bjarne Bergheim | https://sonendo.com |
Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of EDTA that is used to help debride and disinfect the root canal system.
Sonendo Fundamentals Summary
| SONX fundamental statistics | |
|---|---|
| Market Cap | US$43.38m |
| Earnings (TTM) | -US$57.10m |
| Revenue (TTM) | US$37.36m |
1.2x
P/S Ratio-0.8x
P/E RatioIs SONX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SONX income statement (TTM) | |
|---|---|
| Revenue | US$37.36m |
| Cost of Revenue | US$28.03m |
| Gross Profit | US$9.33m |
| Other Expenses | US$66.44m |
| Earnings | -US$57.10m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 24.98% |
| Net Profit Margin | -152.85% |
| Debt/Equity Ratio | 59.2% |
How did SONX perform over the long term?
See historical performance and comparisonValuation
Is SONX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SONX?
Other financial metrics that can be useful for relative valuation.
| What is SONX's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$43.38m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.6x |
| Enterprise Value/EBITDA | -0.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SONX's PS Ratio compare to its peers?
| SONX PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.4x | ||
EAR Eargo | 12.3x | 34.8% | US$44.5m |
SCND Scientific Industries | 3.7x | 52.8% | US$41.3m |
DCTH Delcath Systems | 10.9x | 59.9% | US$41.3m |
ECOR electroCore | 6.6x | 38.8% | US$46.7m |
SONX Sonendo | 1.2x | 34.9% | US$43.4m |
Price-To-Sales vs Peers: SONX is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (8.4x).
Price to Earnings Ratio vs Industry
How does SONX's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: SONX is good value based on its Price-To-Sales Ratio (1.2x) compared to the US Medical Equipment industry average (4.4x)
Price to Sales Ratio vs Fair Ratio
What is SONX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.2x |
| Fair PS Ratio | 2.3x |
Price-To-Sales vs Fair Ratio: SONX is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).
Share Price vs Fair Value
What is the Fair Price of SONX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SONX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SONX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Sonendo forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
39.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SONX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SONX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SONX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SONX's revenue (34.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: SONX's revenue (34.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SONX is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Sonendo performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-26.4%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: SONX is currently unprofitable.
Growing Profit Margin: SONX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if SONX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare SONX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SONX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (2.5%).
Return on Equity
High ROE: SONX has a negative Return on Equity (-126.8%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Sonendo's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SONX's short term assets ($71.7M) exceed its short term liabilities ($14.3M).
Long Term Liabilities: SONX's short term assets ($71.7M) exceed its long term liabilities ($28.6M).
Debt to Equity History and Analysis
Debt Level: SONX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SONX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SONX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SONX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 6.8% each year
Discover healthy companies
Dividend
What is Sonendo current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SONX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SONX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SONX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SONX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SONX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.6yrs
Average management tenure
CEO
Bjarne Bergheim (47 yo)
14.58yrs
Tenure
US$3,205,894
Compensation
Mr. Bjarne Bergheim has been the Chief Executive Officer, President and a Director of Sonendo, Inc since 2008. Mr. Bergheim was our first employee and previously served as our Chief Operating Officer from...
CEO Compensation Analysis
Compensation vs Market: Bjarne's total compensation ($USD3.21M) is above average for companies of similar size in the US market ($USD759.99K).
Compensation vs Earnings: Bjarne's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: SONX's management team is considered experienced (4.6 years average tenure).
Board Members
Experienced Board: SONX's board of directors are considered experienced (8.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SONX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: SONX only recently listed within the past 12 months.
Top Shareholders
Company Information
Sonendo, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Sonendo, Inc.
- Ticker: SONX
- Exchange: NYSE
- Founded: 2006
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$43.384m
- Shares outstanding: 26.62m
- Website: https://sonendo.com
Number of Employees
Location
- Sonendo, Inc.
- 26061 Merit Circle
- Suite 102
- Laguna Hills
- California
- 92653
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/14 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.